Consumers and health professionals are advised that the sponsor of tranylcypromine 10 mg tablets (marketed under the brand name Parnate) has extended the period of expected shortage until 31 January 2021 due to unforeseen delays.
The Therapeutic Goods Administration (TGA) previously published information about this shortage in its medicine shortages database (search for either ‘tranylcypromine’ or ‘Parnate’) and in a safety alert.
The TGA is working closely with the sponsor of this medicine, Amdipharm Mercury (Australia) Pty Ltd, to minimise the impact of the shortage on patients. In particular, the TGA has authorised Amdipharm to supply an overseas-registered brand of tranylcypromine under Section 19A of the Therapeutic Goods Act 1989 to help meet demand.
Amdipharm continues to reserve an emergency supply of tranylcypromine for patients whose pharmacies cannot get stock from their usual suppliers. Pharmacists can contact Amdipharm on